D. Stobaugh

发表

Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Journal of gastrointestinal and liver diseases : JGLD.

Determinants of Palliative Care Utilization Among Patients Hospitalized With Metastatic Gastrointestinal Malignancies

J. Talwalkar, D. Stobaugh, P. Okafor, 2017, The American journal of hospice & palliative care.

Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Journal of the American Academy of Dermatology.

T-Cell Non-Hodgkin's Lymphomas Reported to the FDA AERS With Tumor Necrosis Factor-Alpha (TNF-α) Inhibitors: Results of the REFURBISH Study

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, The American Journal of Gastroenterology.

Effect of Tumor Necrosis Factor–α Inhibitors on Drug-Induced Pancreatitis in Inflammatory Bowel Disease

P. Deepak, D. Stobaugh, 2014, The Annals of pharmacotherapy.

Blockade of arginine vasotocin signaling reduces aggressive behavior and c-Fos expression in the preoptic area and periventricular nucleus of the posterior tuberculum in male Amphiprion ocellaris

C. Yaeger, D. Stobaugh, J. Rhodes, 2014, Neuroscience.

Simulated Comparison of Topical and Oral Formulations of 5-Aminosalicylate for the Treatment of Ulcerative Colitis

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Inflammatory bowel diseases.

Maternal and foetal adverse events with tumour necrosis factor‐alpha inhibitors in inflammatory bowel disease

P. Deepak, D. Stobaugh, 2014, Alimentary pharmacology & therapeutics.

Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis

P. Deepak, D. Stobaugh, Asha R Krishnan, 2015, Rheumatology International.

Socioeconomic Inequalities in the Utilization of Colorectal Stents for the Treatment of Malignant Bowel Obstruction

L. M. Wong Kee Song, J. Talwalkar, D. Stobaugh, 2016, Digestive Diseases and Sciences.

Increased risk of osteoporosis-related fractures in patients with irritable bowel syndrome

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Osteoporosis International.

African Americans Have Better Outcomes for Five Common Gastrointestinal Diagnoses in Hospitals With More Racially Diverse Patients

J. Talwalkar, D. Stobaugh, M. Ryn, 2016, The American Journal of Gastroenterology.

Ischaemic Colitis in Rheumatoid Arthritis Patients Receiving Tumour Necrosis Factor-α Inhibitors: An Analysis of Reports to the US FDA Adverse Event Reporting System

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Drug Safety.

Ischemic Colitis with Type I Interferons Used in the Treatment of Hepatitis C and Multiple Sclerosis: An Evaluation from the Food and Drug Administration Adverse Event Reporting System and Review of the Literature

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, The Annals of pharmacotherapy.

Wheel running can accelerate or delay extinction of conditioned place preference for cocaine in male C57BL/6J mice, depending on timing of wheel access

D. Stobaugh, J. Rhodes, M. Mustroph, 2011, The European journal of neuroscience.

Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Clinical and experimental gastroenterology.

Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.

P. Deepak, D. Stobaugh, M. R. McKenna, 2014, Journal of gastrointestinal and liver diseases : JGLD.

Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2013, Alimentary pharmacology & therapeutics.

Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.

P. Deepak, D. Stobaugh, M. R. McKenna, 2014, Journal of gastrointestinal and liver diseases : JGLD.

Clinical and Experimental Gastroenterology

P. Deepak, D. Stobaugh, E. Ehrenpreis, 2022 .